Advertisement

Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe

  • C. Prakash GyawaliEmail author
Neurogastroenterology and Motility Disorders of the Gastrointestinal Tract (S Rao, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Neurogastroenterology and Motility Disorders of the Gastrointestinal Tract

Abstract

Purpose of Review

Proton pump inhibitor (PPI) use in gastroesophageal reflux disease (GERD) has been redefined, in light of recent advances highlighting GERD phenotypes that respond to PPIs, and fresh revelations of potential risks of long-term PPI therapy.

Recent Findings

Erosive esophagitis predicts excellent response to PPI therapy, but non-erosive reflux disease (NERD) with abnormal reflux parameters on ambulatory reflux monitoring also demonstrates a similar response. In contrast, response is suboptimal in the absence of abnormal reflux parameters. In this setting, if an alternate appropriate indication for PPI therapy does not coexist, risks may outweigh benefits of PPI therapy. Adverse events from long-term PPI therapy continue to be reported, most based on association rather than cause-and-effect.

Summary

Appropriate indications need to be established before embarking on long-term PPI therapy. Future research will define true risks of long-term PPI therapy, and develop alternate management options for acid peptic diseases.

Keywords

Gastroesophageal reflux disease Proton pump inhibitors: heartburn Endoscopy Ambulatory reflux monitoring Esophageal manometry 

Notes

Compliance with Ethical Standards

Conflict of Interest

Prakash Gyawali reports grants and personal fees from Medtronic, Inc. and personal fees from Torax, Quintiles, Ironwood, and Allergan for consulting and speaking, outside the submitted work.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: •Of importance ••Of major importance

  1. 1.
    Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology. 2000;118:S9–31.CrossRefPubMedGoogle Scholar
  2. 2.
    Gralnek IM, Dulai GS, Fennerty MB, et al. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol. 2006;4:1452–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Fass R, Ofman JJ, Gralnek IM, et al. Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Arch Intern Med. 1999;159:2161–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Fass R, Ofman JJ, Sampliner RE, et al. The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis. Aliment Pharmacol Ther. 2000;14:389–96.CrossRefPubMedGoogle Scholar
  5. 5.
    Numans ME, Lau J, de Wit NJ, et al. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med. 2004;140:518–27.CrossRefPubMedGoogle Scholar
  6. 6.
    Sheikh I, Waghray A, Waghray N, et al. Consumer use of over-the-counter proton pump inhibitors in patients with gastroesophageal reflux disease. Am J Gastroenterol. 2014;109:789–94.CrossRefPubMedGoogle Scholar
  7. 7.
    Lanas A. We are using too many PPIs, and we need to stop: a European perspective. Am J Gastroenterol. 2016;111:1085–6.PubMedGoogle Scholar
  8. 8.
    •• Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152:706–15. An excellent description of evidence and expert opinion-based best practice recommendations for appropriate long-term use of proton pump inhibitors. CrossRefPubMedGoogle Scholar
  9. 9.
    Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135:1383–1391, 1391 e1-5.CrossRefPubMedGoogle Scholar
  10. 10.
    Vela MF, Camacho-Lobato L, Srinivasan R, et al. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology. 2001;120:1599–606.CrossRefPubMedGoogle Scholar
  11. 11.
    • Shaheen NJ, Weinberg DS, Denberg TD, et al. Upper endoscopy for gastroesophageal reflux disease: best practice advice from the clinical guidelines committee of the American College of Physicians. Ann Intern Med. 2012;157:808–16. Clinical guidelines for appropriate use of upper endoscopy in gastroesophageal reflux disease. CrossRefPubMedGoogle Scholar
  12. 12.
    • Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108:308–28; quiz 329. Detailed description of indications for diagnostic testing, description of esophageal physiologic tests, and use of diagnostic testing in making management recommendations. CrossRefPubMedGoogle Scholar
  13. 13.
    •• Sigterman KE, van Pinxteren B, Bonis PA, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2013; CD002095. Evidence on the value of short term use of acid suppression and prokinetic therapy in symptomatic foregut syndromes. Google Scholar
  14. 14.
    Khan M, Santana J, Donnellan C, et al. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev. 2007; CD003244.Google Scholar
  15. 15.
    •• Weijenborg PW, Cremonini F, Smout AJ, et al. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis. Neurogastroenterol Motil. 2012;24:747–57, e350. Meta-analysis detailing the clinical value of proton pump inhibitors in erosive and well characterized nonerosive reflux disease. CrossRefPubMedGoogle Scholar
  16. 16.
    •• Aziz Q, Fass R, Gyawali CP, et al. Functional esophageal disorders. Gastroenterology. 2016;150:1368–79. Current ROME IV diagnostic criteria for functional esophageal disorders and the basis for these criteria. CrossRefGoogle Scholar
  17. 17.
    Weijenborg PW, Smout AJ, Bredenoord AJ. Esophageal acid sensitivity and mucosal integrity in patients with functional heartburn. Neurogastroenterol Motil. 2016;28:1649–54.CrossRefPubMedGoogle Scholar
  18. 18.
    Savarino E, Zentilin P, Frazzoni M, et al. Characteristics of gastro-esophageal reflux episodes in Barrett’s esophagus, erosive esophagitis and healthy volunteers. Neurogastroenterol Motil. 2010;22:1061–e280.CrossRefPubMedGoogle Scholar
  19. 19.
    •• Roman S, Gyawali CP, Savarino E, et al. Ambulatory reflux monitoring for diagnosis of gastro-esophageal reflux disease: Update of the Porto consensus and recommendations from an international consensus group. Neurogastroenterol Motil. 2017; Evidence and expert opinion on appropriate utilization of ambulatory reflux monitoring in GERD Google Scholar
  20. 20.
    •• Scarpignato C, Gatta L, Zullo A, et al. Effective and safe proton pump inhibitor therapy in acid-related diseases—A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14:179. A valuable resource detailing state-of-the-art evidence for appropriate use of proton pump inhibitors. CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Kahrilas PJ, Jonsson A, Denison H, et al. Regurgitation is less responsive to acid suppression than heartburn in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2012;10:612–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Chang AB, Lasserson TJ, Gaffney J, et al. Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults. Cochrane Database Syst Rev. 2011; CD004823.Google Scholar
  23. 23.
    Kahrilas PJ, Hughes N, Howden CW. Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease. Gut. 2011;60:1473–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Vaezi MF, Richter JE, Stasney CR, et al. Treatment of chronic posterior laryngitis with esomeprazole. Laryngoscope. 2006;116:254–60.CrossRefPubMedGoogle Scholar
  25. 25.
    Kahrilas PJ, Howden CW, Hughes N. Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease. Am J Gastroenterol. 2011;106:1419–25; quiz 1426.CrossRefPubMedGoogle Scholar
  26. 26.
    Hersh MJ, Sayuk GS, Gyawali CP. Long-term therapeutic outcome of patients undergoing ambulatory pH monitoring for chronic unexplained cough. J Clin Gastroenterol. 2010;44:254–60.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Kiljander TO, Harding SM, Field SK, et al. Effects of esomeprazole 40 mg twice daily on asthma: a randomized placebo-controlled trial. Am J Respir Crit Care Med. 2006;173:1091–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Cremonini F, Wise J, Moayyedi P, et al. Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a metaanalysis. Am J Gastroenterol. 2005;100:1226–32.CrossRefPubMedGoogle Scholar
  29. 29.
    Wang WH, Huang JQ, Zheng GF, et al. Is proton pump inhibitor testing an effective approach to diagnose gastroesophageal reflux disease in patients with noncardiac chest pain?: a meta-analysis. Arch Intern Med. 2005;165:1222–8.CrossRefPubMedGoogle Scholar
  30. 30.
    • Boghossian TA, Rashid FJ, Thompson W, et al. Deprescribing versus continuation of chronic proton pump inhibitor use in adults. Cochrane Database Syst Rev. 2017;3:CD011969. Evidence for and against on demand use of acid suppression. PubMedGoogle Scholar
  31. 31.
    Vasiliadis KV, Viazis N, Vlachogiannakos J, et al. Efficacy of three different dosages of esomeprazole in the long-term management of reflux disease: a prospective, randomized study, using the wireless bravo pH system. Am J Gastroenterol. 2010;105:308–13.CrossRefPubMedGoogle Scholar
  32. 32.
    Johnson DA, Benjamin SB, Vakil NB, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol. 2001;96:27–34.CrossRefPubMedGoogle Scholar
  33. 33.
    Inadomi JM, Jamal R, Murata GH, et al. Step-down management of gastroesophageal reflux disease. Gastroenterology. 2001;121:1095–100.CrossRefPubMedGoogle Scholar
  34. 34.
    • Jobe BA, Richter JE, Hoppo T, et al. Preoperative diagnostic workup before antireflux surgery: an evidence and experience-based consensus of the esophageal diagnostic advisory panel. J Am Coll Surg. 2013;217:586–97. Expert opinion on preoperative diagnostic work up prior to antireflux surgery for GERD. CrossRefPubMedGoogle Scholar
  35. 35.
    Richter JE, Pandolfino JE, Vela MF, et al. Utilization of wireless pH monitoring technologies: a summary of the proceedings from the esophageal diagnostic working group. Dis Esophagus. 2013;26:755–65.CrossRefPubMedGoogle Scholar
  36. 36.
    Herregods TV, Troelstra M, Weijenborg PW, et al. Patients with refractory reflux symptoms often do not have GERD. Neurogastroenterol Motil. 2015;27:1267–73.CrossRefPubMedGoogle Scholar
  37. 37.
    • Hershcovici T, Fass R. Step-by-step management of refractory gastresophageal reflux disease. Dis Esophagus. 2013;26:27–36. An approach to evaluation and management of refractory symptoms in GERD. CrossRefPubMedGoogle Scholar
  38. 38.
    Poh CH, Gasiorowska A, Navarro-Rodriguez T, et al. Upper GI tract findings in patients with heartburn in whom proton pump inhibitor treatment failed versus those not receiving antireflux treatment. Gastrointest Endosc. 2010;71:28–34.CrossRefPubMedGoogle Scholar
  39. 39.
    • Dellon ES, Gonsalves N, Hirano I, et al. ACG clinical guideline: evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol. 2013;108:679–92; quiz 693. Evidence based description of the use of proton pump inhibitors in the diagnosis and management of eosinophilic esophagitis. CrossRefPubMedGoogle Scholar
  40. 40.
    • Gyawali CP, Roman S, Bredenoord AJ, et al. Classification of esophageal motor findings in gastro-esophageal reflux disease: Conclusions from an international consensus group. Neurogastroenterol Motil. 2017; Characterization of findings on esophageal high resolution manometry in GERD Google Scholar
  41. 41.
    Leodolter A, Kulig M, Brasch H, et al. A meta-analysis comparing eradication, healing and relapse rates in patients with helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther. 2001;15:1949–58.CrossRefPubMedGoogle Scholar
  42. 42.
    Scott D, Weeks D, Melchers K, et al. The life and death of Helicobacter pylori. Gut. 1998;43(Suppl 1):S56–60.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Kavitt RT, Cifu AS. Management of Helicobacter pylori infection. JAMA. 2017;317:1572–3.CrossRefPubMedGoogle Scholar
  44. 44.
    Hunt RH, Lanas A, Stichtenoth DO, et al. Myths and facts in the use of anti-inflammatory drugs. Ann Med. 2009;41:423–37.CrossRefPubMedGoogle Scholar
  45. 45.
    Ito T, Igarashi H, Jensen RT. Zollinger-Ellison syndrome: recent advances and controversies. Curr Opin Gastroenterol. 2013;29:650–61.CrossRefPubMedGoogle Scholar
  46. 46.
    Gralnek IM, Dumonceau JM, Kuipers EJ, et al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2015;47:a1–46.CrossRefPubMedGoogle Scholar
  47. 47.
    • Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol. 2012;107:345–60; quiz 361. Current management of peptic ulcer bleeding. CrossRefPubMedGoogle Scholar
  48. 48.
    • Lucendo AJ, Arias A, Molina-Infante J. Efficacy of proton pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14:13–22 e1. Evidence for PPI use in eosinophilic esophagitis. CrossRefPubMedGoogle Scholar
  49. 49.
    Kavitt RT, Hirano I, Vaezi MF. Diagnosis and treatment of eosinophilic esophagitis in adults. Am J Med. 2016;129:924–34.CrossRefPubMedGoogle Scholar
  50. 50.
    Bardou M, Quenot JP, Barkun A. Stress-related mucosal disease in the critically ill patient. Nat Rev Gastroenterol Hepatol. 2015;12:98–107.CrossRefPubMedGoogle Scholar
  51. 51.
    Alhazzani W, Alenezi F, Jaeschke RZ, et al. Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Crit Care Med. 2013;41:693–705.CrossRefPubMedGoogle Scholar
  52. 52.
    Gardner TB, Robertson DJ. Stress ulcer prophylaxis in non-critically ill patients: less may be more. Am J Gastroenterol. 2006;101:2206–8.CrossRefPubMedGoogle Scholar
  53. 53.
    Alshamsi F, Belley-Cote E, Cook D, et al. Efficacy and safety of proton pump inhibitors for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis of randomized trials. Crit Care. 2016;20:120.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Shin S. Evaluation of costs accrued through inadvertent continuation of hospital-initiated proton pump inhibitor therapy for stress ulcer prophylaxis beyond hospital discharge: a retrospective chart review. Ther Clin Risk Manag. 2015;11:649–57.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Dent J, Vakil N, Jones R, et al. Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond tudy. Gut. 2010;59:714–21.CrossRefPubMedGoogle Scholar
  56. 56.
    •• Talley NJ, Ford AC. Functional dyspepsia. N Engl J Med. 2015;373:1853–63. Modern evaluation and management of functional dyspepsia. CrossRefPubMedGoogle Scholar
  57. 57.
    Lacy BE, Talley NJ, Locke GR 3rd, et al. Review article: current treatment options and management of functional dyspepsia. Aliment Pharmacol Ther. 2012;36:3–15.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Moayyedi P, Soo S, Deeks J, et al. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006; CD001960.Google Scholar
  59. 59.
    Moayyedi P, Delaney BC, Vakil N, et al. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology. 2004;127:1329–37.CrossRefPubMedGoogle Scholar
  60. 60.
    •• Vaezi MF, Yang YX, Howden CW. Complications of Proton Pump Inhibitor Therapy. Gastroenterol. 2017; Detailed discussion of how to evaluate published literature addressing risks of long-term PPI therapy Google Scholar
  61. 61.
    • Kia L, Kahrilas PJ. Therapy: risks associated with chronic PPI use - signal or noise? Nat Rev Gastroenterol Hepatol. 2016;13:253–4. Expert analysis of risks of proton pump inhibitor use. CrossRefPubMedGoogle Scholar
  62. 62.
    Yadlapati R, Kahrilas PJ. When is proton pump inhibitor use appropriate? BMC Med. 2017;15:36.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Johnson DA, Oldfield ECT. Reported side effects and complications of long-term proton pump inhibitor use: dissecting the evidence. Clin Gastroenterol Hepatol. 2013;11:458–64; quiz e37-8.CrossRefPubMedGoogle Scholar
  64. 64.
    Sierra F, Suarez M, Rey M, et al. Systematic review: proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther. 2007;26:545–53.CrossRefPubMedGoogle Scholar
  65. 65.
    Blank ML, Parkin L, Paul C, et al. A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int. 2014;86:837–44.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176:238–46.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Moledina DG, Perazella MA. PPIs and kidney disease: from AIN to CKD. J Nephrol. 2016;29:611–6.CrossRefPubMedGoogle Scholar
  68. 68.
    Klepser DG, Collier DS, Cochran GL. Proton pump inhibitors and acute kidney injury: a nested case-control study. BMC Nephrol. 2013;14:150.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med. 2006;355:1834–6.CrossRefPubMedGoogle Scholar
  70. 70.
    Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail. 2015;37:1237–41.CrossRefPubMedGoogle Scholar
  71. 71.
    Sharara AI, Chalhoub JM, Hammoud N, et al. Low prevalence of hypomagnesemia in long-term recipients of proton pump inhibitors in a managed care cohort. Clin Gastroenterol Hepatol. 2016;14:317–21.CrossRefPubMedGoogle Scholar
  72. 72.
    Masclee GM, Coloma PM, Kuipers EJ, et al. Increased risk of microscopic colitis with use of proton pump inhibitors and non-steroidal anti-inflammatory drugs. Am J Gastroenterol. 2015;110:749–59.CrossRefPubMedGoogle Scholar
  73. 73.
    Capurso G, Marignani M, Attilia F, et al. Lansoprazole-induced microscopic colitis: an increasing problem? Results of a prospecive case-series and systematic review of the literature. Dig Liver Dis. 2011;43:380–5.CrossRefPubMedGoogle Scholar
  74. 74.
    Furuya-Kanamori L, Stone JC, Clark J, et al. Comorbidities, exposure to medications, and the risk of community-acquired Clostridium difficile infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2015;36:132–41.CrossRefPubMedGoogle Scholar
  75. 75.
    Zacharioudakis IM, Zervou FN, Pliakos EE, et al. Colonization with toxinogenic C. difficile upon hospital admission, and risk of infection: a systematic review and meta-analysis. Am J Gastroenterol. 2015;110:381–90; quiz 391.CrossRefPubMedGoogle Scholar
  76. 76.
    Dial S, Alrasadi K, Manoukian C, et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ. 2004;171:33–8.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther. 2011;34:1269–81.CrossRefPubMedGoogle Scholar
  78. 78.
    Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102:2047–56; quiz 2057.CrossRefPubMedGoogle Scholar
  79. 79.
    Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11:483–90.CrossRefPubMedGoogle Scholar
  80. 80.
    Xu HB, Wang HD, Li CH, et al. Proton pump inhibitor use and risk of spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis. Genet Mol Res. 2015;14:7490–501.CrossRefPubMedGoogle Scholar
  81. 81.
    Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med. 2008;149:391–8.CrossRefPubMedGoogle Scholar
  82. 82.
    Estborn L, Joelson S. Frequency and time to onset of community-acquired respiratory tract infections in patients receiving esomeprazole: a retrospective analysis of patient-level data in placebo-controlled studies. Aliment Pharmacol Ther. 2015;42:607–13.CrossRefPubMedGoogle Scholar
  83. 83.
    Lambert AA, Lam JO, Paik JJ, et al. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One. 2015;10:e0128004.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Ito T, Jensen RT. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep. 2010;12:448–57.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Lam JR, Schneider JL, Quesenberry CP, et al. Proton pump inhibitor and histamine-2 receptor antagonist use and iron deficiency. Gastroenterology. 2017;152:821–829 e1.CrossRefPubMedGoogle Scholar
  86. 86.
    Lam JR, Schneider JL, Zhao W, et al. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013;310:2435–42.CrossRefPubMedGoogle Scholar
  87. 87.
    Ngamruengphong S, Leontiadis GI, Radhi S, et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011;106:1209–18; quiz 1219.CrossRefPubMedGoogle Scholar
  88. 88.
    Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947–53.CrossRefPubMedGoogle Scholar
  89. 89.
    Gomm W, von Holt K, Thome F, et al. Association of Proton Pump Inhibitors With Risk of Dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73:410–6.CrossRefPubMedGoogle Scholar
  90. 90.
    Haenisch B, von Holt K, Wiese B, et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci. 2015;265:419–28.CrossRefPubMedGoogle Scholar
  91. 91.
    Goldstein FC, Steenland K, Zhao L, et al. Proton pump inhibitors and risk of mild cognitive impairment and dementia. J Am Geriatr Soc. 2017;Google Scholar
  92. 92.
    Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363:1909–17.CrossRefPubMedGoogle Scholar
  93. 93.
    Lahner E, Annibale B, Delle FG. Systematic review: impaired drug absorption related to the co-administration of antisecretory therapy. Aliment Pharmacol Ther. 2009;29:1219–29.CrossRefPubMedGoogle Scholar
  94. 94.
    Cats A, Schenk BE, Bloemena E, et al. Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment. Hum Pathol. 2000;31:684–90.CrossRefPubMedGoogle Scholar
  95. 95.
    Jalving M, Koornstra JJ, Wesseling J, et al. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther. 2006;24:1341–8.CrossRefPubMedGoogle Scholar
  96. 96.
    Song H, Zhu J, Lu D. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions. Cochrane Database Syst Rev. 2014;12:CD010623.Google Scholar
  97. 97.
    Shah NH, LePendu P, Bauer-Mehren A, et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One. 2015;10:e0124653.CrossRefPubMedPubMedCentralGoogle Scholar
  98. 98.
    Quenot JP, Thiery N, Barbar S. When should stress ulcer prophylaxis be used in the ICU? Curr Opin Crit Care. 2009;15:139–43.CrossRefPubMedGoogle Scholar
  99. 99.
    •• de Bortoli N, Martinucci I, Savarino E, et al. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they? Neurogastroenterol Motil. 2014;26:28–35. Follow-up and phenotyping of responders and non-responders of short-term PPI therapy administered for heartburn with normal endoscopy. CrossRefPubMedGoogle Scholar
  100. 100.
    Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med. 2006;166:965–71.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.Division of GastroenterologyWashington University School of MedicineSt. LouisUSA

Personalised recommendations